Mandate

Vinge advises Surgical Science Sweden AB (publ) in connection with the acquisition of Mimic Technologies Inc and with a directed share issue

January 26, 2021 M&A

Vinge has advised Surgical Science Sweden AB (publ) (“Surgical Science”) in connection with its acquisition of all shares in Mimic Technologies Inc for an initial consideration of SEK 150 million with a maximum deferred contingent consideration of SEK 130 million.

In order to finance the acquisition, Surgical Science has carried out a directed share issue. The directed share issue comprised of 3,279,676 newly issued shares at a subscription price of SEK 98.30 per share, whereby Surgical Science will receive gross proceeds of approximately SEK 322 million before transaction related costs. The subscription price has been determined through an accelerated book‑building procedure and corresponds to a premium of approximately 1 per cent to the closing price of SEK 97.40 per share on 20 January 2021 on Nasdaq First North Growth Market.

Surgical Science is a world leader in the manufacture of virtual reality simulators for evidence-based laparoscopic and endoscopic training. The simulators enable surgeons and other medical specialists to train and improve their psychomotor skills and instrument handling before entering the operating room. In parallel with its own products, Surgical Science works with simulation solutions for medical technology companies that develop surgical instruments for clinical use, such as robotic surgery.

Vinge’s team has consisted of Fredrik Sonander (M&A) and Edin Agic (Capital Markets).

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025